

Eugènia Pujol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8110334/publications.pdf>

Version: 2024-02-01

8
papers

209
citations

1478505

6
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

379
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatic regulation of VLDL receptor by PPAR α and FGF21 modulates non-alcoholic fatty liver disease. <i>Molecular Metabolism</i> , 2018, 8, 117-131.	6.5	77
2	Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer's Disease. <i>Neurotherapeutics</i> , 2020, 17, 1825-1835.	4.4	45
3	Heme-Regulated eIF2 α Kinase Modulates Hepatic FGF21 and Is Activated by PPAR α Deficiency. <i>Diabetes</i> , 2016, 65, 3185-3199.	0.6	31
4	Pentafluorosulfanyl-containing Triclocarban Analogs with Potent Antimicrobial Activity. <i>Molecules</i> , 2018, 23, 2853.	3.8	25
5	Oral administration of a new HRI activator as a new strategy to improve high-fat diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21. <i>British Journal of Pharmacology</i> , 2019, 176, 2292-2305.	5.4	14
6	Antibacterial activity of novel benzopolycyclic amines. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 290-296.	3.0	7
7	<i>In Vitro</i> , <i>In Vivo</i> , and Absorption, Distribution, Metabolism, and Excretion Evaluation of SF ₅ -Containing N,N'-Diarylureas as Antischistosomal Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0061521.	3.2	7
8	Synthesis, Characterization and HPLC Analysis of the (1S,2S,5R)-Diastereomer and the Enantiomer of the Clinical Candidate AR-15512. <i>Molecules</i> , 2021, 26, 906.	3.8	3